Evaluation of the Efficacy of Rosuvastatin in Daily Practice in Untreated High Risk Patients (CHALLENGE)

AstraZeneca0 个研究点目标入组 2,660 人开始时间: 2003年9月最近更新: 2007年12月17日

适应症

试验速览

阶段: 不适用
状态: 已完成
发起方: AstraZeneca
入组人数: 2,660

研究概览研究设计入排标准研究者记录与标识符相似试验

研究概览

简要总结

In an observational multi-centre study (CHALLENGE), the effects were assessed of starting treatment with low doses of rosuvastatin in statin naive patients with a history of coronary heart disease (CHD), peripheral vascular disease (PVD), cerebrovascular accident (CVA), transient ischemic attack (TIA) or diabetes (DM), on low-density lipoprotein cholesterol (LDL-C) goal achievement. Also proportional changes in LDL-C, high-density lipoprotein cholesterol (HDL-C), total cholesterol (TC), triglycerides (TG) and the ratio TC/HDL-C were studied.

研究设计

研究类型: Observational
时间视角: Prospective

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Patients eligible for the study were high-risk patients with a documented history of CHD, PVD, cerebrovascular atherosclerotic disease, DM II or DM I with microalbuminuria. LDL-C had to be > 2.5 mmol/l and the patient did not use any cholesterol lowering medication during the last 3 months preceding inclusion. The specialist made the decision to start treatment with rosuvastatin irrespective of study participation. Patient approved to place anonymous results at the disposal of AstraZeneca

排除标准

•Exclusion criteria included patients familiar with muscular pain, myopathy or liver function disorders (inclusive elevation of serum transaminases), patients with familial dyslipideamia like familial hypercholesterolaemia and familial combined hyperlipid

研究者

发起方

AstraZeneca

申办方类型

Industry

相似试验

已完成

不适用

Assessment of the Efficacy of Rosuvastatin in Patient Groups With a Dissimilar Risk Profile in an Observational Study (HEROS)Coronary Heart DiseaseCerebrovascular AccidentDiabetesHypercholesterolemiaPeripheral Vascular Disease

NCT00660764AstraZeneca

已完成

3 期

Polaris - Crestor 40 mg vs Atorvastatin 80 mg for 26 WeeksHypercholesterolemiaCoronary Heart Disease

NCT00653588AstraZeneca

已完成

不适用

Evaluation of the Efficacy of Rosuvastatin in Daily Practice (TARGET)HypercholesterolemiaCoronary Heart Disease

NCT00396110AstraZeneca3,889

已完成

3 期

A Study to Investigate the Effect of Rosuvastatin (CRESTOR®) on High Density Lipoprotein Kinetics in Patients With the Metabolic SyndromeMetabolic SyndromeDyslipidemia

NCT00240305AstraZeneca15

Unknown

4 期

Efficacy and Safety Study of 5 mg and 10 mg RosuvastatinDyslipidemia

NCT01613729D16 Pharma & Biotec Ltd.2,000